Logo

Max Planck Partners with Evotec Technologies and Definiens to Develop High Throughput RNAi and Imaging Platform

Sep 19, 2003

NEW YORK, Sept. 19 (GenomeWeb News) - The Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany announced today that it is teaming up with German companies Evotec Technologies of Hamburg and Definiens of Munich to develop a new platform for high throughput RNAi and cell-based screening and image analysis.

 

The partnership is part of "biosaxony," a Saxon biotech initiative endorsed by the state government of Saxony, Germany.

 

MPI-CBG was the first institute to publish a genome-scale analysis using RNAi in C. elegans, and will now provide the assays, location and laboratory facilities for the study. The Institute will use Evotec's confocal optics-based fluorescent imaging platform Opera to collect data and Definiens' object-oriented image analysis platform called Cognition Network Technology to analyze the data.

 

The group hopes to commercialize the methods they develop for industry use.

 

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.